관리자의 임명
이 발표에는 7년 유럽 연합(철회)법에 따라 영국 법률의 일부인 규정(EU) No 596/2014의 2018조 목적을 위한 내부 정보가 포함되어 있습니다.
월 20 2024
리뉴런 그룹 PLC
("리뉴런", NS "그룹" 아니면 그 "기업 정보")
관리자의 임명
Further to the announcement of its decision to appoint administrators on 20 March 2024 (the "이전 공지"), ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces that the Company has now appointed Stephen Cork and Mark Smith of Cork Gully LLP as joint administrators to the Company, along with the following subsidiaries: ReNeuron Holdings Limited, ReNeuron Limited and ReNeuron (UK) Limited.
The Board have taken this action to protect the interests of the Group's creditors and the Company's ordinary shares remain suspended from trading on AIM.
Notwithstanding the appointment of administrators, the Company is still in negotiations regarding a potential number of corporate actions including raising additional equity financing and/or securing a financing facility and/or entering into M&A discussions and/or realising value in certain of the Group's physical and intellectual assets. However, there is no guarantee that such negotiations will successfully conclude, and should they not, any residual value to transpire from the administration process will be distributed to the agreed creditors and, should funds permit, the Company's shareholders with the Company being dissolved thereafter.
The Company's shareholders can contact the administrator team via the enquiries details noted below.
본 공지사항에 정의되지 않은 대문자로 표시된 용어는 문맥상 달리 요구되지 않는 한 이전 공지사항에서 정의된 의미를 갖습니다.
추후 발표 될 예정입니다.
The person responsible for arranging the release of this announcement on behalf of the Company is Iain Ross, Executive Chairman of the Company.
문의 :
Cork Gully LLP | +44 (0)20 7268 2150 또는 | ||
Stephen Cork, Joint Administrator | |||
Mark Smith, Joint Administrator | |||
| |||
리뉴런 | www.reneuron.com/investors | ||
Iain Ross, 회장 | Walbrook PR을 통해 | ||
존 호킨스, 최고재무책임자 | |||
Allenby Capital Limited(지명 고문 및 Broker) | +44 (0)20 3328 5656 | ||
James Reeve/George Payne/ Dan Dearden-Williams (Corporate Finance) | |||
Stefano Aquilino/Kelly Gardiner(영업 및 기업 중개) | |||
Walbrook PR(미디어 및 투자자 관계) | +44 (0)20 7933 8780 또는 [이메일 보호] | ||
폴 맥마누스 / 앨리스 우딩스 | +44 (0)7980 541 893 / +44 (0)7407 804 654 | ||
리뉴론 소개
ReNeuron은 복잡한 약물 전달을 위한 맞춤형 세포 표적 기능을 갖춘 독점적인 줄기 세포 유래 엑소좀 기반 약물 전달 플랫폼을 개발했습니다.
Through the generation of several unique and scalable exosome producer cell lines, our CustomEX? platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
ReNeuron의 주식은 런던 AIM 시장에서 RENE.L이라는 기호로 거래됩니다. 자세한 내용은 방문 www.reneuron.com
This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions.
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.